Biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for cancer.
Century Therapeutics, Inc. is a pioneering biotechnology company focused on advancing revolutionary allogeneic cell therapies tailored for the treatment of both solid tumors and hematological malignancies. At the forefront of its innovative pipeline is CNTY-101, an allogeneic therapy derived from induced pluripotent stem cells (iPSCs) and engineered with chimeric antigen receptors (CARs) to target CD19, specifically designed for patients with relapsed or refractory B-cell lymphoma. Additionally, Century Therapeutics is actively developing CNTY-103, a CAR-iNK therapy targeting CD133 + EGFR for recurrent glioblastoma, and CNTY-102, a CAR-iT therapy targeting CD19 + CD79b for relapsed B-cell lymphoma and other B-cell malignancies.
The company's robust pipeline also includes CNTY-104, a multi-specific CAR-iT or CAR-iNK candidate aimed at acute myeloid leukemia, and CNTY-106, another multi-specific CAR-iNK or CAR-iT candidate targeting multiple myeloma. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, Century Therapeutics combines cutting-edge scientific research with a commitment to developing transformative therapies that address critical unmet needs in oncology.
Century Therapeutics is dedicated to pushing the boundaries of cell therapy through its strategic focus on allogeneic approaches, aiming to broaden accessibility and enhance the efficacy of cancer treatments. The company's innovative platform leverages iPSC technology to create off-the-shelf therapies that have the potential to revolutionize cancer care, offering new hope to patients worldwide.
Driven by a mission to improve patient outcomes, Century Therapeutics continues to expand its portfolio of next-generation cell therapies. Through collaborative partnerships and rigorous clinical development, the company aims to accelerate the delivery of novel treatments and redefine the standard of care in oncology.